Increasing Prevalence of Diabetes and Launch of Integrated Diabetes Solutions to Augment Growth of Insulin Market
Insulin is a soluble,
polysaccharide glycan hormone produced by pancreatic beta cells in the
pancreas; it is presently considered the most important hormones of the human
body. It controls the metabolism of protein, fats, and carbohydrates by
stimulating the absorption of glucose in the bloodstream into fat, liver and
muscle tissues. It also stimulates the utilization of proteins for energy production
in the cells and helps in the storage of glycogen, a glucose-energy reserve in
the liver and muscles. Glycogen is responsible for storing glucose and other
nutrients during physical exercise. The release of insulin in the bloodstream
causes stimulation of carbohydrate metabolism in the liver, resulting in low
blood glucose levels.
Market
Dynamics
Increasing prevalence
of diabetes is expected to propel growth of the global insulin market. For
instance, according to the study, “Global and regional diabetes
prevalence estimates for 2019 and projections for 2030 and 2045: Results from
the International Diabetes Federation Diabetes Atlas, 9th edition”, published
in the journal Diabetes Research and Clinical Practice, in September 2019, 463
million people are expected to suffer from diabetes in 2019 worldwide and the
number is expected to reach 578 million by 2030 and 700 million by 2045.
Launch of integrated
diabetes solutions is expected to offer lucrative growth opportunities for
players in the global insulin
market. For instance, in October 2019, Tandem Diabetes
Care Inc. partnered with Abbott to develop and commercialize integrated
diabetes solutions that combine Abbott's glucose sensing technology with Tandem's
insulin delivery systems. Moreover, availability of treatment options for insulin
resistance is also expected to aid in growth of the market. For instance, in
December 2020, Tonix Pharmaceuticals Holding Corp., a clinical-stage
biopharmaceutical company, announced an agreement whereby Tonix has acquired
the exclusive license to the University of Geneva’s technology for using
oxytocin to treat insulin resistance and related syndromes, including obesity,
from privately held Katana Pharmaceuticals, Inc.
Competitive
Analysis
Major players operating
in the global insulin market include, Eli Lilly and Company, Novo Nordisk A/ S,
Julphar Gulf Pharmaceutical Industries, Arecor Limited, Sanofi S.A., Biocon
Limited, GlaxoSmithKline, and Wockhardt.
Major players operating
in the global insulin market are focused on R&D to expand their product
portfolio. For instance, in December 2020, Arecor Limited announced dosing of
the first patient in a Phase I clinical trial for its second clinical stage
product, an ultra-concentrated rapid acting insulin, AT278.

Comments
Post a Comment